PIK3CA and female reproductive organ cancer: Both EGFR and ErbB2 receptors can activate various signaling pathways, including both the PI3K and MAPK (via RAS-RAF oncogenes) which provide survival signaling, cell growth to tumors and contribute to the overall acquisition of chemoresistance in gynecological cancers.